Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

EMBO Journal

Volumn 23, Issue 5, 2004, Pages 1144-1154

  Insinga, Alessandra ^a   Monestiroli, Silvia ^a,c   Ronzoni, Simona ^a   Carbone, Roberta ^a   Pearson, Mark ^a,e   Pruneri, Giancarlo ^a   Viale, Giuseppe ^a   Appella, Ettore ^b   Pelicci, PierGiuseppe ^a,c   Minucci, Saverio ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Histone deacetylase; P53; PML; PML RAR; Promyelocytic leukemia

Indexed keywords

HISTONE DEACETYLASE; HYBRID PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR;

ACETYLATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLAST CELL; CONTROLLED STUDY; DEACETYLATION; ENZYME INACTIVATION; ENZYME RELEASE; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENOTOXICITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN STABILITY; WILD TYPE;

ACETYLATION; ALLELES; ANIMALS; CELL LINE; DNA-BINDING PROTEINS; HISTONE DEACETYLASES; MICE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 12144287125     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600109     Document Type: Article

References (57)

1. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193
2. Appella E, Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772
3. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468
4. Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P (1991) Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer 3: 332-337
5. Deppert W, Haug M, Steinmayer T (1987) Modulation of p53 protein expression during cellular transformation with simian virus 40. Mol Cell Biol 7: 4453-4463
6. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082
7. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027
8. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195
9. Gottifredi V, Prives C (2001) P53 and PML: new partners in tumor suppression. Trends Cell Biol 11: 184-187
10. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978
11. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818
12. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Pelicci PG (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83: 10-25
13. Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Nicoletti I, Peschle C, Pelicci PG (1996) Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J 15: 4949-4958
14. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Paolo Pandolfi P (2000) The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736
15. He L, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6: 1131-1141
16. Heimfeld S, Hudak S, Weissman I, Rennick D (1991) The in vitro responseof phenotypically defined mouse stem cells and myeloerythroid growth factors. Proc Natl Acad Sci USA 88: 9902-9906
17. Hiorns LR, Swansburry GH, Mehta T, Dainton MG, Treleaven J, Powles RL, Catovsky D (1997) Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 96: 314-321
18. Invernizzi R, Pecci A, Bellotti L, Ascari E (2001) Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma 42: 481-489
19. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331-1340
20. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054-1072
21. Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM (2001) BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 193: 531-543
22. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400
23. Le Beau MM, Bitts S, Davis EM, Kogan SC (2002) Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99: 2985-2991
24. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
25. Lin RJ, Egan DA, Evans RM (1999) Molecular genetics of acute promyelocytic leukemia. Trends Genet 15: 179-184
26. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW (2002) The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743-750
27. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI (1995) A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690
28. Longo L, Trecca D, Biondi A, Lo Coco F, Grignani F, Maiolo AT, Pelicci PG, Neri A (1993) Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leuk Lymphoma 11: 405-410
29. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064
30. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y (2003) PML protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278: 33134-33141
31. Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202
32. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG (2000) Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5: 811-820
33. Minucci, S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanziani E, Gobbi A, Pelicci PG (2002) PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100: 2989-2995
34. Minucci S, Nervi C, Lo Coco F, Pelicci PG (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20: 3110-3115
35. Minucci S, Pelicci PG (1999) Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 10: 215-225
36. Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H, Helin K (2001) Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3: 552-558
37. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL (1997) Identification of a lineage of multipotent hematopoietic progenitors. Development 124: 1929-1939
38. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210
39. Pearson M, Pelicci PG (2001) PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20: 7250-7256
40. Prives C (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8
41. Prives C, Manley J (2001) Why is p53 acetylated? Cell 107: 815-818
42. Quelle FW, Wang J, Feng J, Wang D, Cleveland JE, Ihle JN, Zambetti GP (1998) Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 12: 1099-1107
43. Rabbitts TH (1991) Translocations, master genes, and diffe rences between the origins of acute and chronic leukemias. Cell 67: 641-644
44. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372: 143-149
45. Ryan KM, Phillips AC, Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337
46. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841
47. Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Storkel S, Ortel J, Kolbe K, Huber C, Huhn D, Neubauer A (1996) Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 57: 230-240
48. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737
49. Soussi T, Béroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233-239
50. Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. Science 241: 58-62
51. Trecca D, Longo L, Biondi A, Cro L, Calori R, Grignani F, Maiolo AT, Pelicci PG, Neri A (1994) Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 46: 304-309
52. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
53. Vousden KH (2000) p53: death star. Cell 103: 691-694
54. Warrell Jr RP, de The H, Wang ZY, Degos L (1993) Acute promyelocytic leukemia. N Engl J Med 329: 177-189
55. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB, Maki CG (2003) Physical and functional interactions between PML and MDM2. J Biol Chem 278: 29288-29297
56. Westervelt P, Ley TJ (1999) Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood 93: 2143-2148
57. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ (2000) Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 97: 13306-13311